Ticker >

Panacea Biotec share price

Panacea Biotec Ltd.

NSE: PANACEABIO BSE: 531349 SECTOR: Pharmaceuticals & Drugs  35k   100   22

121.55
-1.95 (-1.58%)
NSE: 28 Mar 4:00 PM

Price Summary

Today's High

₹ 127.6

Today's Low

₹ 120.3

52 Week High

₹ 202.5

52 Week Low

₹ 107.55

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationFair
The stock’s market price justifies its intrinsic value.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

744.5 Cr.

Enterprise Value

803.7 Cr.

No. of Shares

6.13 Cr.

P/E

0

P/B

2.25

Face Value

₹ 1

Div. Yield

0 %

Book Value (TTM)

₹  53.97

CASH

43.25 Cr.

DEBT

102.45 Cr.

Promoter Holding

73.59 %

EPS (TTM)

₹  -2.41

Sales Growth

9.16%

ROE

-23.64 %

ROCE

-11.36%

Profit Growth

6.45 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year9.16%
3 Year-19.33%
5 Year-14.85%

Profit Growth

1 Year6.45%
3 Year12.61%
5 Year-4.8%

ROE%

1 Year-23.64%
3 Year-15.34%
5 Year-12.67%

ROCE %

1 Year-11.36%
3 Year-9.4%
5 Year-3.12%

Debt/Equity

0.3146

Price to Cash Flow

-69.31

Interest Cover Ratio

-5.23529411764706

CFO/PAT (5 Yr. Avg.)

0

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Dec 2023 73.59 0
Sep 2023 73.59 0
Jun 2023 73.59 0
Mar 2023 73.59 0
Dec 2022 73.59 0
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has an efficient Cash Conversion Cycle of -108.572594397288 days.
  • The company has a high promoter holding of 73.59%.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 19.2003476924277.

 Limitations

  • The company has shown a poor revenue growth of -19.3298536025381% for the Past 3 years.
  • Company has a poor ROE of -15.3377678726393% over the past 3 years.
  • Company has a poor ROCE of -9.39859088144389% over the past 3 years
  • Company has low Interest coverage ratio of -5.23529411764706.
  • Company has contingent liabilities of 639.763 Cr.
  • Company has negative cash flow from operations of -10.742.
  • The company has a low EBITDA margin of -17.1717185054282% over the past 5 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
Net Sales 71.97 75.02 89.41 94.59 95.23
Total Expenditure 59.68 71.59 82.6 84.63 88.59
Operating Profit 12.29 3.43 6.81 9.96 6.64
Other Income 9.71 10.27 3.34 2.13 3.05
Interest 2.68 2.7 3.46 3.55 3.41
Depreciation 6.08 5.9 5.4 5.34 5.21
Exceptional Items 0 0 0 0 0
Profit Before Tax 13.24 5.1 1.29 3.2 1.07
Tax 0 24.79 0 0 0.64
Profit After Tax 13.24 -19.69 1.29 3.2 0.43
Adjusted EPS (Rs) 2.16 -3.21 0.21 0.52 0.07

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Net Sales 444.16 489.68 343.56 235.5 257.07
Total Expenditure 590.77 479.63 343.07 308.17 319.69
Operating Profit -146.61 10.05 0.49 -72.67 -62.63
Other Income 8.12 43.91 20.75 12.57 34.44
Interest 104.63 147.25 7.52 7.04 10.06
Depreciation 53.71 27.29 26.57 26.43 24.5
Exceptional Items 334.01 -15.4 0 0 0
Profit Before Tax 37.18 -135.97 -12.85 -93.58 -62.75
Tax 10.61 17.1 1.56 0 24.79
Net Profit 26.57 -153.07 -14.44 -93.58 -87.54
Adjusted EPS (Rs.) 4.34 -24.99 -2.35 -15.28 -14.29

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Equity and Liabilities
Share Capital 6.13 6.13 6.13 6.13 6.13
Total Reserves 412.35 886.61 502.04 408.97 319.53
Borrowings 88.3 60.43 62.08 84.1 102.4
Other N/C liabilities 165.16 186.72 191.99 187.36 214.38
Current liabilities 921.09 167.35 197.67 244.16 250.85
Total Liabilities 1593.02 1307.23 961.76 933.31 895.38
Assets
Net Block 496.44 447.29 398.44 416.13 385.31
Capital WIP 2.95 3.66 12.93 0.86 16.42
Intangible WIP 0.15 0.08 0.04 0.01 11.42
Investments 2.54 2.55 0.27 0.27 0.27
Loans & Advances 173.95 186.5 187.45 188.82 225.33
Other N/C Assets 0.89 52.84 106.82 78.38 57.48
Current Assets 916.11 614.32 255.8 248.83 199.13
Total Assets 1593.02 1307.23 961.76 933.31 895.38
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Profit from operations 37.18 -135.97 -12.88 -93.58 -62.75
Adjustment -67.89 204.95 31.82 35.98 10.43
Changes in Assets & Liabilities 137.45 -143.93 20.3 5.73 42.67
Tax Paid 0.42 -7.9 -0.98 -0.82 -1.09
Operating Cash Flow 107.16 -82.86 38.27 -52.69 -10.74
Investing Cash Flow -10.27 -16.58 -37.32 39.54 2.41
Financing Cash Flow -98.45 109.39 -7.2 9.83 9.01
Net Cash Flow -1.57 9.96 -6.26 -3.32 0.67

Corporate Actions

Investors Details

PARTICULARS Dec 2022% Mar 2023% Jun 2023% Sep 2023% Dec 2023%
promoters 73.59 73.59 73.59 73.59 73.59
dr. rajesh jain 41.17 49.33 49.33 49.33 49.33
first lucre partnership c... 3.68 3.68 3.68 3.68 3.68
mr. sandeep jain 16.38 16.38 16.38 16.38 16.38
mrs. nirmala jain 4.10 4.10 4.10 4.10 4.10
second lucre partnership ... 0.09 0.09 0.09 0.09 0.09
mr. soshil kumar jain 8.16 - - - -
PARTICULARS Dec 2022% Mar 2023% Jun 2023% Sep 2023% Dec 2023%
investors 26.41 26.41 26.41 26.41 26.41
investor education and pr... - 0.18 0.17 0.17 0.17
serum institute of india ... 7.61 7.60 6.97 1.10 -
investor education and pr... 0.18 - - - -

Annual Reports

Ratings & Research Reports

Company Presentations

  • PresentationQ1FY22 29 Jul 2021

Company News

Panacea Biotec informs about newspaper publication 13 Mar 2024, 5:07PM Panacea Biotec informs about notice of postal ballot12 Mar 2024, 5:19PM Panacea Biotec - Quaterly Results13 Feb 2024, 2:50PM Panacea Biotec - Quaterly Results13 Feb 2024, 2:50PM Panacea Biotec - Quaterly Results13 Feb 2024, 2:50PM Panacea Biotec informs about board meeting30 Jan 2024, 4:41PM Panacea Biotec launches fully-liquid wP-IPV based Pentavalent vaccine ‘EasyFourPol’14 Dec 2023, 6:16PM Panacea Biotec’s arm launches Paclitaxel Protein-Bound Particles for Injectable Suspension28 Oct 2023, 11:33AM Panacea Biotec informs about updates 28 Oct 2023, 10:36AM USFDA concludes inspection at Baddi facility of Panacea Biotec’s arm 13 Oct 2023, 10:09AM Panacea Biotec informs about disclosure12 Sep 2023, 5:26PM Panacea Biotec informs about BRSR 7 Sep 2023, 4:53PM Panacea Biotec informs about shares dematerialized 6 Sep 2023, 12:37PM Panacea Biotec - Quaterly Results12 Aug 2023, 3:17PM Panacea Biotec - Quaterly Results12 Aug 2023, 3:17PM Panacea Biotec informs about launch of news products 15 Jun 2023, 2:24PM Panacea Biotec’s arm launches new range of pediatric food & nutritional products15 Jun 2023, 11:40AM Panacea Biotec - Quaterly Results30 May 2023, 2:53PM Panacea Biotec informs about closure of trading window30 Mar 2023, 11:21AM Panacea Biotec - Quaterly Results14 Feb 2023, 1:43PM Panacea Biotec - Quaterly Results14 Feb 2023, 1:43PM Panacea Biotec - Quaterly Results14 Feb 2023, 1:43PM Panacea Biotec donates 125,000 SDVs to Cuba17 Jan 2023, 12:50PM Panacea Biotec informs about disclosure of related party transactions29 Nov 2022, 3:43PM Panacea Biotec - Quaterly Results14 Nov 2022, 4:54PM Panacea Biotec - Quaterly Results14 Nov 2022, 4:54PM Panacea Biotec gets UNICEF, PAHO awards for supply of Pentavalent Vaccine11 Oct 2022, 9:38AM Panacea Biotec - Quaterly Results9 Aug 2022, 3:30PM Panacea Biotec - Quaterly Results9 Aug 2022, 3:30PM Panacea Biotec informs about postal ballot notice28 Jun 2022, 5:14PM Panacea Biotec informs about disclosure10 Jun 2022, 2:24PM USFDA conducts inspection at Panacea Biotec’s arm’s facility at Baddi 10 Jun 2022, 9:47AM Panacea Biotec - Quaterly Results18 May 2022, 3:01PM Panacea Biotec - Quaterly Results18 May 2022, 3:01PM Panacea Biotec - Quaterly Results18 May 2022, 3:01PM Panacea Biotec informs about appointment of additional director2 Apr 2022, 11:47AM Panacea Biotec informs about resignation of director10 Mar 2022, 4:32PM Panacea Biotec - Quaterly Results14 Feb 2022, 4:16PM Panacea Biotec - Quaterly Results14 Feb 2022, 4:16PM Panacea Biotec supplies first shipment of second component of Sputnik V vaccine produced in India7 Sep 2021, 9:28AM Panacea Biotec informs about newspaper advertisement 26 Jul 2021, 3:48PM Panacea Biotec informs about outcome of board meeting24 Jul 2021, 10:12AM Panacea Biotec gets manufacturing license for Sputnik V vaccine5 Jul 2021, 9:14AM Panacea Biotec, Russian Direct Investment Fund launch production of Russian Sputnik V vaccine24 May 2021, 4:17PM Adar Poonawalla offloads entire stake in Panacea Biotec18 May 2021, 1:17PM Panacea Biotec files suit seeking to restrain Sanofi from marketing fully liquid hexavalent vaccine18 May 2021, 12:30PM Panacea Biotec informs about updates17 May 2021, 2:46PM Panacea Biotec informs about dematerialized shares7 May 2021, 3:59PM Panacea Biotec, RDIF agree to produce 100 million doses of Sputnik V vaccine in India per year6 Apr 2021, 10:42AM Panacea Biotec gets warning letter from USFDA for Baddi plant5 Oct 2020, 11:33AM

Panacea Biotec Stock Price Analysis and Quick Research Report. Is Panacea Biotec an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Panacea Biotec and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Panacea Biotec cash from the operating activity was Rs -10.742 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Panacea Biotec has a Debt to Equity ratio of 0.3146 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Panacea Biotec , the EPS growth was 6.44599645234557 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Panacea Biotec has OPM of -24.36213127317 % which is a bad sign for profitability.
     
  • ROE: Panacea Biotec have a poor ROE of -23.6367440887215 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Panacea Biotec is Rs 121.55. One can use valuation calculators of ticker to know if Panacea Biotec share price is undervalued or overvalued.
Last Updated on:
Brief about Panacea Biotec

Panacea Biotec Limited Financials: Check Share Price, Balance Sheet, Annual Report, Quarterly Results, Shareholding, Company Profile and News for Company Analysis

Panacea Biotec Limited is a leading biotechnology company based in India. With a focus on healthcare and pharmaceuticals, the company has a strong presence in research, development, manufacturing, and marketing of vaccines, generics, and biopharmaceuticals. Panacea Biotec Limited aims to provide affordable healthcare solutions for patients around the world.

Panacea Biotec Limited - Share Price

Stay updated on the latest share price of Panacea Biotec Limited by visiting our stock analysis page. Our website provides real-time stock prices, allowing investors to track the performance of the company's shares.

Panacea Biotec Limited - Balance Sheet

To gain insight into the financial position of Panacea Biotec Limited, utilize our pre-built screening tools available on our website. These tools enable long-term stock investors to analyze the company's balance sheet. Additionally, through our premium features, investors can make use of fair value calculation tools such as DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis.

Panacea Biotec Limited - Annual Report

The annual reports of Panacea Biotec Limited can be found as downloadable documents on our website. These reports provide comprehensive information about the company's performance, financials, operational highlights, and future prospects. Long-term stock investors can closely examine these reports to make informed investment decisions.

Panacea Biotec Limited - Dividend

For dividend analysis of Panacea Biotec Limited, our website provides access to dividend data and historical records. Investors can evaluate the company's dividend history to understand its dividend-paying practices and assess the potential income generated from their investments.

Panacea Biotec Limited - Quarterly Results

Along with the annual reports, we offer quarterly results of Panacea Biotec Limited for download on our website. These reports give investors a timely overview of the company's performance during specific quarters. Combined with our premium features, investors can use various analysis tools to gain deeper insights into the company's financial health.

Panacea Biotec Limited - Stock Price

On our website, you can find the latest stock prices of Panacea Biotec Limited, enabling you to closely monitor the price movements of the company's shares. Stay updated with real-time price data to make well-informed investment decisions.

Panacea Biotec Limited - Price Chart

Utilize the price charts available on our website to visualize the historical price movements of Panacea Biotec Limited's stocks. These charts help investors identify patterns and trends, enabling them to make more accurate predictions about future stock performance.

Panacea Biotec Limited - News

For the latest company news and updates about Panacea Biotec Limited, visit our website. Stay informed about significant developments, such as product launches, regulatory approvals, collaborations, and acquisitions, which may impact the company's stock performance.

Panacea Biotec Limited - Concall Transcripts

At our website, we provide downloadable concall transcripts of Panacea Biotec Limited. These transcripts contain records of the company's conference calls with analysts and investors, showcasing discussions on various aspects of the company's performance, strategies, and future plans.

Panacea Biotec Limited - Investor Presentations

Gain a deeper understanding of Panacea Biotec Limited's business strategies, growth plans, and market positioning by accessing investor presentations on our website. These presentations provide valuable insights into the company's operations, performance highlights, and future outlook.

Panacea Biotec Limited - Promoters

Panacea Biotec Limited is driven by a team of dedicated promoters who are professionals in the field of biotechnology and healthcare. Our website provides detailed information about the company's promoters, their expertise, and their contributions towards the company's growth.

Panacea Biotec Limited - Shareholders

Discover the major shareholders of Panacea Biotec Limited on our website. We offer insights into institutional investors and their holdings, helping investors understand the ownership structure of the company and its potential impact on stock performance.

By utilizing our website's comprehensive stock analysis tools and accessing downloadable reports, transcripts, and presentations, long-term stock investors can perform a detailed analysis of Panacea Biotec Limited. Stay informed, make informed investment decisions, and potentially benefit from the growth and prospects of this leading biotechnology company.

Read More
X